首页 > 最新文献

Therapeutic delivery最新文献

英文 中文
Enhanced bioavailability and efficacy in antimalarial treatment through QbD approach enteric encased inclusion delivery. 通过 QbD 方法肠溶包合物给药提高抗疟治疗的生物利用度和疗效。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-09-03 DOI: 10.1080/20415990.2024.2377948
Neha Bajwa, Preet Amol Singh, Sumant Kumar, Girish Chandra Arya, Ashish Baldi

Aim: In this study, we aimed to prepare enteric encapsulated spheroids containing inclusion complex using quality by design approach.Methods: A Box-Behnken design was employed to determine effects of variables on selected responses. Risk assessment was conducted using Ishikawa fishbone diagram. A model with a p-value was less than 0.5 for being a significant error of model was determined based on significance 'lack of fit' value. Spheroids were formulated using the extrusion spheronization technique and were characterized using analytical techniques.Results: In vitro release was performed in both acidic (pH 1.2) and simulated intestinal (pH 6.8) conditions. Permeability studies demonstrated tenfold enhancement compared with arteether. In vivo studies further validated increase of 51.8% oral bioavailability. Ex vivo studies revealed 3.4-fold enhancement in antimalarial activity compared with arteether.Conclusion: These findings highlight effectiveness of inclusion complexation technique as a viable approach to enhance solubility and bioavailability for drugs with low aqueous solubility.

目的:在本研究中,我们旨在采用质量设计法制备含有包涵复合物的肠道包裹球。方法采用方框-贝肯设计来确定变量对选定反应的影响。使用石川鱼骨图进行风险评估。根据显著性 "不拟合 "值,确定 p 值小于 0.5 的模型为显著误差模型。使用挤压球化技术配制球体,并使用分析技术对其进行表征。结果:在酸性(pH 值为 1.2)和模拟肠道(pH 值为 6.8)条件下进行了体外释放。渗透性研究表明,与蒿甲醚相比,蒿甲醚的渗透性提高了十倍。体内研究进一步验证了口服生物利用率提高了 51.8%。体内外研究表明,与蒿甲醚相比,其抗疟活性提高了 3.4 倍。结论:这些研究结果凸显了包合复合物技术的有效性,它是提高低水溶性药物的溶解度和生物利用度的一种可行方法。
{"title":"Enhanced bioavailability and efficacy in antimalarial treatment through QbD approach enteric encased inclusion delivery.","authors":"Neha Bajwa, Preet Amol Singh, Sumant Kumar, Girish Chandra Arya, Ashish Baldi","doi":"10.1080/20415990.2024.2377948","DOIUrl":"10.1080/20415990.2024.2377948","url":null,"abstract":"<p><p><b>Aim:</b> In this study, we aimed to prepare enteric encapsulated spheroids containing inclusion complex using quality by design approach.<b>Methods:</b> A Box-Behnken design was employed to determine effects of variables on selected responses. Risk assessment was conducted using Ishikawa fishbone diagram. A model with a <i>p</i>-value was less than 0.5 for being a significant error of model was determined based on significance 'lack of fit' value. Spheroids were formulated using the extrusion spheronization technique and were characterized using analytical techniques.<b>Results:</b> <i>In vitro</i> release was performed in both acidic (pH 1.2) and simulated intestinal (pH 6.8) conditions. Permeability studies demonstrated tenfold enhancement compared with arteether. <i>In vivo</i> studies further validated increase of 51.8% oral bioavailability. <i>Ex vivo</i> studies revealed 3.4-fold enhancement in antimalarial activity compared with arteether.<b>Conclusion:</b> These findings highlight effectiveness of inclusion complexation technique as a viable approach to enhance solubility and bioavailability for drugs with low aqueous solubility.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry update: the latest developments in the field of therapeutic delivery, April 2024. 行业更新:2024 年 4 月治疗传递领域的最新发展。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI: 10.1080/20415990.2024.2376520
Peter Timmins
{"title":"Industry update: the latest developments in the field of therapeutic delivery, April 2024.","authors":"Peter Timmins","doi":"10.1080/20415990.2024.2376520","DOIUrl":"10.1080/20415990.2024.2376520","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing therapy with nano-based delivery systems: exploring the bioactive properties and effects of apigenin. 利用纳米给药系统增强治疗效果:探索芹菜素的生物活性特性和作用。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-09-11 DOI: 10.1080/20415990.2024.2386928
Girish Kumar, Pushpika Jain, Tarun Virmani, Ashwani Sharma, Md Sayeed Akhtar, Saad A Aldosari, Mohd Faiyaz Khan, Sofia O D Duarte, Pedro Fonte

Apigenin, a potent natural flavonoid, has emerged as a key therapeutic agent due to its multifaceted medicinal properties in combating various diseases. However, apigenin's clinical utility is greatly limited by its poor water solubility, low bioavailability and stability issues. To address these challenges, this review paper explores the innovative field of nanotechnology-based delivery systems, which have shown significant promise in improving the delivery and effectiveness of apigenin. This paper also explores the synergistic potential of co-delivering apigenin with conventional therapeutic agents. Despite the advantageous properties of these nanoformulations, critical challenges such as scalable production, regulatory approvals and comprehensive long-term safety assessments remain key hurdles in their clinical adoption which must be addressed for commercialization of apigenin-based formulations.

芹菜素是一种有效的天然类黄酮,因其在防治各种疾病方面的多重药用特性,已成为一种重要的治疗药物。然而,芹菜素的水溶性差、生物利用率低和稳定性问题极大地限制了它的临床应用。为了应对这些挑战,本综述论文探讨了基于纳米技术的给药系统这一创新领域。本文还探讨了芹菜素与传统治疗药物联合给药的协同潜力。尽管这些纳米制剂具有优势特性,但可规模化生产、监管审批和全面的长期安全性评估等关键挑战仍然是临床应用的主要障碍,必须加以解决,才能实现芹菜素制剂的商业化。
{"title":"Enhancing therapy with nano-based delivery systems: exploring the bioactive properties and effects of apigenin.","authors":"Girish Kumar, Pushpika Jain, Tarun Virmani, Ashwani Sharma, Md Sayeed Akhtar, Saad A Aldosari, Mohd Faiyaz Khan, Sofia O D Duarte, Pedro Fonte","doi":"10.1080/20415990.2024.2386928","DOIUrl":"https://doi.org/10.1080/20415990.2024.2386928","url":null,"abstract":"<p><p>Apigenin, a potent natural flavonoid, has emerged as a key therapeutic agent due to its multifaceted medicinal properties in combating various diseases. However, apigenin's clinical utility is greatly limited by its poor water solubility, low bioavailability and stability issues. To address these challenges, this review paper explores the innovative field of nanotechnology-based delivery systems, which have shown significant promise in improving the delivery and effectiveness of apigenin. This paper also explores the synergistic potential of co-delivering apigenin with conventional therapeutic agents. Despite the advantageous properties of these nanoformulations, critical challenges such as scalable production, regulatory approvals and comprehensive long-term safety assessments remain key hurdles in their clinical adoption which must be addressed for commercialization of apigenin-based formulations.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry updates in the field of therapeutic delivery in June 2024. 2024 年 6 月治疗给药领域的行业动态。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-10-11 DOI: 10.1080/20415990.2024.2408214
Mengistie Diress, Armin Mooranian, Hani Al-Salami
{"title":"Industry updates in the field of therapeutic delivery in June 2024.","authors":"Mengistie Diress, Armin Mooranian, Hani Al-Salami","doi":"10.1080/20415990.2024.2408214","DOIUrl":"https://doi.org/10.1080/20415990.2024.2408214","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and optimization of guaifenesin sustained release mini-tablets for adult and geriatric patients. 开发和优化用于成人和老年患者的愈创木酚缓释小药片。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-10-03 DOI: 10.1080/20415990.2024.2406216
Mahshid Samadi, Mitra Jelvehgari, Sara Salatin

Aim: The main aim of this study was to formulate and optimize sustained release mini-tablets of guaifenesin.Materials & methods: Guaifenesin granules were successfully prepared using different blend ratios of carnauba wax to drug by melt granulation method. The properties of granules were further modified by combining them with ethyl cellulose. The obtained granules were then mixed and compressed into mini-tablets using a tablet press machine. The resulting mini-tablets were characterized in terms of weight, thickness, hardness, drug content and in vitro drug release.Results: Mini-tablets with 1:6 carnauba wax to drug ratio showed superior physicochemical characteristics, releasing about 100.03% of guaifenesin over 8 h. Ethyl cellulose offers a great potential to accurately control drug release from mini-tablets.Conclusion: The prepared mini-tablets seem to be a very promising alternative to guaifenesin conventional formulations and can be used in adults and elderly people.

目的:本研究的主要目的是配制和优化愈创甘油醚缓释小药片:采用不同的棕榈蜡与药物混合比例,通过熔融造粒法成功制备了愈创木酚颗粒。通过与乙基纤维素结合,进一步改变了颗粒剂的性质。然后将得到的颗粒混合并用压片机压制成小药片。对所得迷你药片的重量、厚度、硬度、药物含量和体外药物释放进行了表征:结果:棕榈蜡与药物比例为 1:6 的迷你药片显示出优异的理化特性,在 8 小时内释放了约 100.03% 的愈创木酚:所制备的迷你片剂似乎是一种非常有前景的瓜奈酚传统制剂替代品,可用于成人和老年人。
{"title":"Development and optimization of guaifenesin sustained release mini-tablets for adult and geriatric patients.","authors":"Mahshid Samadi, Mitra Jelvehgari, Sara Salatin","doi":"10.1080/20415990.2024.2406216","DOIUrl":"10.1080/20415990.2024.2406216","url":null,"abstract":"<p><p><b>Aim:</b> The main aim of this study was to formulate and optimize sustained release mini-tablets of guaifenesin.<b>Materials & methods:</b> Guaifenesin granules were successfully prepared using different blend ratios of carnauba wax to drug by melt granulation method. The properties of granules were further modified by combining them with ethyl cellulose. The obtained granules were then mixed and compressed into mini-tablets using a tablet press machine. The resulting mini-tablets were characterized in terms of weight, thickness, hardness, drug content and <i>in vitro</i> drug release.<b>Results:</b> Mini-tablets with 1:6 carnauba wax to drug ratio showed superior physicochemical characteristics, releasing about 100.03% of guaifenesin over 8 h. Ethyl cellulose offers a great potential to accurately control drug release from mini-tablets.<b>Conclusion:</b> The prepared mini-tablets seem to be a very promising alternative to guaifenesin conventional formulations and can be used in adults and elderly people.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry Update, May 2024. 行业最新情况,2024 年 5 月。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-08-08 DOI: 10.1080/20415990.2024.2383162
Elaine Harris
{"title":"Industry Update, May 2024.","authors":"Elaine Harris","doi":"10.1080/20415990.2024.2383162","DOIUrl":"10.1080/20415990.2024.2383162","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted drug delivery to the thrombus by fusing streptokinase with a fibrin-binding peptide (CREKA): an in silico study. 通过融合链激酶和纤维蛋白结合肽(CREKA)向血栓靶向给药:一项硅学研究。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-04-30 DOI: 10.4155/tde-2023-0107
Mohammad Soroosh Hajizade, Mohammad Javad Raee, Seyed Nooreddin Faraji, Fakhrossadat Farvadi, Maryam Kabiri, Sedigheh Eskandari, Ali Mohammad Tamaddon

Aim: Streptokinase has poor selectivity and provokes the immune response. In this study, we used in silico studies to design a fusion protein to achieve targeted delivery to the thrombus. Materials & methods: Streptokinase was analyzed computationally for mapping. The fusion protein modeling and quality assessment were carried out on several servers. The enzymatic activity and the stability of the fusion protein and its complex with plasminogen were assessed through molecular docking analysis and molecular dynamics simulation respectively. Results: Physicochemical properties analysis, protein quality assessments, protein-protein docking and molecular dynamics simulations predicted that the designed fusion protein is functionally active. Conclusion: Our results showed that this fusion protein might be a prospective candidate as a novel thrombolytic agent with better selectivity.

目的:链激酶的选择性较差,会引起免疫反应。在本研究中,我们利用硅学研究设计了一种融合蛋白,以实现对血栓的靶向给药。材料与方法:通过计算分析链激酶的图谱。在多个服务器上进行了融合蛋白建模和质量评估。通过分子对接分析和分子动力学模拟,分别评估了融合蛋白的酶活性和稳定性及其与纤溶酶原的复合物。结果理化性质分析、蛋白质质量评估、蛋白质-蛋白质对接和分子动力学模拟预测所设计的融合蛋白质具有功能活性。结论我们的研究结果表明,这种融合蛋白可能是一种具有更好选择性的新型溶栓药物。
{"title":"Targeted drug delivery to the thrombus by fusing streptokinase with a fibrin-binding peptide (CREKA): an <i>in silico</i> study.","authors":"Mohammad Soroosh Hajizade, Mohammad Javad Raee, Seyed Nooreddin Faraji, Fakhrossadat Farvadi, Maryam Kabiri, Sedigheh Eskandari, Ali Mohammad Tamaddon","doi":"10.4155/tde-2023-0107","DOIUrl":"10.4155/tde-2023-0107","url":null,"abstract":"<p><p><b>Aim:</b> Streptokinase has poor selectivity and provokes the immune response. In this study, we used <i>in silico</i> studies to design a fusion protein to achieve targeted delivery to the thrombus. <b>Materials & methods:</b> Streptokinase was analyzed computationally for mapping. The fusion protein modeling and quality assessment were carried out on several servers. The enzymatic activity and the stability of the fusion protein and its complex with plasminogen were assessed through molecular docking analysis and molecular dynamics simulation respectively. <b>Results:</b> Physicochemical properties analysis, protein quality assessments, protein-protein docking and molecular dynamics simulations predicted that the designed fusion protein is functionally active. <b>Conclusion:</b> Our results showed that this fusion protein might be a prospective candidate as a novel thrombolytic agent with better selectivity.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of fexofenadine self-microemulsifying delivery systems: an efficient way to improve intestinal permeability. 开发非索非那定自微乳化给药系统:改善肠道渗透性的有效方法。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-06-28 DOI: 10.1080/20415990.2024.2363635
Ziba Islambulchilar, Ashkan Barfar, Shahla Mirzaeei

Aim: The present study aimed to prepare and evaluate fexofenadine self-microemulsifying drug-delivery systems (SMEDDS) formulation and to determine and compare its intestinal permeability using in situ single-pass intestinal perfusion (SPIP) technique.Methods: Fexofenadine-loaded SMEDDS were prepared and optimized. Droplet size, polydispersity index, zeta potential, drug release and intestinal permeability were evaluated.Results: Optimized formulation consisted of 15% oil, 80% surfactant and 5% cosolvent. Droplet size and drug loading of optimized formulation was 13.77 nm and 60 mg/g and it has released 90% of its drug content. Intestinal permeability of fexofenadine was threefold enhanced in SMEDDS compared with free fexofenadine.Conclusion: The results of our study revealed that SMEDDS could be a promising tool for oral delivery of fexofenadine with enhanced dissolution rate and intestinal permeability.

目的:本研究旨在制备和评估非索非那定自微乳化给药系统(SMEDDS)制剂,并采用原位单通道肠道灌注(SPIP)技术测定和比较其肠道渗透性。研究方法制备并优化了负载非索非那定的 SMEDDS。对液滴大小、多分散指数、ZETA电位、药物释放和肠道渗透性进行了评估。结果显示优化配方由 15%的油、80% 的表面活性剂和 5% 的共溶剂组成。优化配方的液滴大小和载药量分别为 13.77 纳米和 60 毫克/克,释放了 90% 的药物成分。与游离非索非那定相比,SMEDDS 中非索非那定的肠道渗透性提高了三倍。结论我们的研究结果表明,SMEDDS 可以提高非索非那定的溶出率和肠道渗透性,是一种很有前途的口服给药工具。
{"title":"Development of fexofenadine self-microemulsifying delivery systems: an efficient way to improve intestinal permeability.","authors":"Ziba Islambulchilar, Ashkan Barfar, Shahla Mirzaeei","doi":"10.1080/20415990.2024.2363635","DOIUrl":"10.1080/20415990.2024.2363635","url":null,"abstract":"<p><p><b>Aim:</b> The present study aimed to prepare and evaluate fexofenadine self-microemulsifying drug-delivery systems (SMEDDS) formulation and to determine and compare its intestinal permeability using <i>in situ</i> single-pass intestinal perfusion (SPIP) technique.<b>Methods:</b> Fexofenadine-loaded SMEDDS were prepared and optimized. Droplet size, polydispersity index, zeta potential, drug release and intestinal permeability were evaluated.<b>Results:</b> Optimized formulation consisted of 15% oil, 80% surfactant and 5% cosolvent. Droplet size and drug loading of optimized formulation was 13.77 nm and 60 mg/g and it has released 90% of its drug content. Intestinal permeability of fexofenadine was threefold enhanced in SMEDDS compared with free fexofenadine.<b>Conclusion:</b> The results of our study revealed that SMEDDS could be a promising tool for oral delivery of fexofenadine with enhanced dissolution rate and intestinal permeability.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
March Industry News. 三月行业新闻。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-06-28 DOI: 10.1080/20415990.2024.2365621
Fiona McCartney
{"title":"March Industry News.","authors":"Fiona McCartney","doi":"10.1080/20415990.2024.2365621","DOIUrl":"10.1080/20415990.2024.2365621","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia. 纳米技术辅助联合给药:治疗急性髓性白血病的渐进方法。
IF 3 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 Epub Date: 2024-09-13 DOI: 10.1080/20415990.2024.2394012
Neelam Poonia, Nikita Vijay Jadhav, Davuluri Mamatha, Manoj Garg, Atul Kabra, Amit Bhatia, Shreesh Ojha, Viney Lather, Deepti Pandita

Acute myeloid leukemia (AML), a heterogeneous hematopoietic cancer prevalent in adults, has been a leading cause of leukemia-associated deaths for decades. Despite advancements in understanding its pathology and pharmacological targets, therapeutic strategies have seen minimal change. The standard treatment, combining cytarabine and anthracycline, has persisted, accompanied by challenges such as pharmacokinetic issues and non-specific drug delivery, leading to severe side effects. Nanotechnology offers a promising solution through combination drug delivery. FDA-approved CPX351 (VYXEOS™) a liposomal formulation delivering doxorubicin and cytarabine, exemplifies enhanced therapeutic efficacy. Ongoing research explores various nanocarriers for delivering multiple bioactives, addressing drug targeting, pharmacokinetics and chemoresistance. This review highlights nanotechnology-based combination therapies for the effective management of AML, presenting a potential breakthrough in leukemia.

急性髓性白血病(AML)是一种多发于成人的异质性造血癌症,几十年来一直是白血病相关死亡的主要原因。尽管人们对其病理和药理靶点的认识不断进步,但治疗策略的改变却微乎其微。将阿糖胞苷和蒽环类药物结合使用的标准治疗方法一直沿用至今,但却面临着药代动力学问题和非特异性给药等挑战,导致严重的副作用。纳米技术通过联合给药提供了一种前景广阔的解决方案。美国食品和药物管理局批准的 CPX351(VYXEOS™)是一种可递送多柔比星和阿糖胞苷的脂质体制剂,是提高疗效的典范。目前正在进行的研究探索了多种纳米载体,用于递送多种生物活性物质,解决药物靶向、药代动力学和化疗耐药性等问题。本综述重点介绍了有效治疗急性髓细胞性白血病的纳米技术联合疗法,为白血病领域带来了潜在的突破。
{"title":"Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia.","authors":"Neelam Poonia, Nikita Vijay Jadhav, Davuluri Mamatha, Manoj Garg, Atul Kabra, Amit Bhatia, Shreesh Ojha, Viney Lather, Deepti Pandita","doi":"10.1080/20415990.2024.2394012","DOIUrl":"10.1080/20415990.2024.2394012","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML), a heterogeneous hematopoietic cancer prevalent in adults, has been a leading cause of leukemia-associated deaths for decades. Despite advancements in understanding its pathology and pharmacological targets, therapeutic strategies have seen minimal change. The standard treatment, combining cytarabine and anthracycline, has persisted, accompanied by challenges such as pharmacokinetic issues and non-specific drug delivery, leading to severe side effects. Nanotechnology offers a promising solution through combination drug delivery. FDA-approved CPX351 (VYXEOS™) a liposomal formulation delivering doxorubicin and cytarabine, exemplifies enhanced therapeutic efficacy. Ongoing research explores various nanocarriers for delivering multiple bioactives, addressing drug targeting, pharmacokinetics and chemoresistance. This review highlights nanotechnology-based combination therapies for the effective management of AML, presenting a potential breakthrough in leukemia.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic delivery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1